Ceragenix Epiceram product phase 4 results positive

Analysis of: Ceragenix Announces Results from Phase IV Study of EpiCeram(TM) Meet All Primary and Secondary Endpoints www.irconnect.com

Implications: The recent Epiceram phase 4 data comparing it to Cutivate are positive, and bode well for the product. The concept of barrier repair makes sense in light of the recent findings in regards to the genetic basis of atopic dermatitis. Repairing the barrier with Epiceram will reduce inflammation, and the results show that this reduction approaches that with a steroid. The biggest potential is using Epiceram as the base for many other compounds/conditions where the barrier is impaired like psoriasis, etc.Analysis: This study will increase the market significantly, because there is a non steroid option which has good efficacy, and repairs the barrier. Epiceram can be used as the base into which other compounds can be mixed, so that you can treat the primary condition, and repair the barrier. Dermatologists and other physicians, as well as patients are looking for a new treatment modality for atopic dermatitis, especially one that will have minimal or no side effects.